RenegadeXBio, PBC

RenegadeXBio, PBC is a biotechnology firm focused on delivering innovative solutions that streamline processes in the life sciences sector. Their expertise lies in developing advanced biotechnological applications for various industries. Founded in 2020 by Craig Rouskey, Julia Russotti, and Shari Geffon, RenegadeXBio, PBC operates from its headquarters in San Francisco, US. The company specializes in biotechnology solutions and has successfully completed 4 deals, with its latest funding round being a Seed round in May 2020, raising USD 0.

330 mn from investor SOSV. Craig Rouskey, the CEO, has a background in leading innovative firms in the biotechnology space. RenegadeXBio provides cutting-edge biotechnology solutions designed to meet the diverse needs of clients across multiple sectors. Their core offerings include a comprehensive array of biotechnological applications that enhance operational efficiency and facilitate research and development projects.

With an emphasis on addressing challenges in workflow management and data analysis, their solutions support small to medium-sized enterprises as well as large corporations, primarily in the life sciences, healthcare, and pharmaceutical industries. The company targets markets in North America and Western Europe, where there is a growing demand for advanced biotechnological tools. The revenue model for RenegadeXBio is based on a subscription framework, allowing clients to access their suite of biotechnology solutions on an ongoing basis. Clients can choose from annual or monthly subscription plans, which ensure they receive continuous updates and support.

The flagship product, known for its advanced features, is available in tiered pricing structures to cater to various customer segments, from startups to established enterprises. This approach not only ensures accessibility but also maximizes recurring revenue opportunities, with direct-to-consumer transactions facilitating swift access to critical technology tools. RenegadeXBio is working on expanding its product lineup, focusing on developing new biotechnological applications aimed at enhancing research capabilities and operational workflows. The company has plans to enter additional markets in Asia and South America by 2023, driven by the increasing global demand for biotechnological solutions.

The recent Seed funding round raised in May 2020, amounting to USD 0. 330 mn, will be utilized to drive these initiatives, including product development and market expansion efforts.